Follow
Acarix AB
Nasdaq First North Sweden (Sweden)
Acarix AB operates as a medical technology company which is engaged in developing diagnostic tests for cardiovascular diseases primarily in Europe, China, and the United States. Its main activities are to develop, produce and market a new cardiovascular diagnostic method and similar equipment for the same and related services. The company develops the CADScor acoustic device that is designed to be used by doctors to help assess patients' risk of coronary artery disease.
Sector:
HEALTH CARE
>
Medical Devices
New issue
Price
1.50 SEK
Subscription period
09 Oct - 25 Oct 2019
Instruments & Events
The shares and options available for this company. Including past events like IPOs, direct listings and exercise periods.
Type
Ticker
ISIN
Market
SHARE
ACARIX
SE0009268717
Nasdaq First North Sweden
Sweden (SE)
Details of share in Acarix AB with ticker ACARIX
Status
Active
Order book id
Amount of instruments
23 027 376
Par value
1.2000
Market cap
Currency
SEK
Segment
First North Premier
First trading date
19 Dec 2016
Terms
Type
Price
Pre-money valuation
Time
IPO
17.60 SEK
265M SEK
28 Nov - 07 Dec 2016
IPO in Acarix AB
Market
Nasdaq First North Sweden
Subscription period
28 Nov - 07 Dec 2016
Subscription price
Price per share
17.60 SEK
Target to raise
140 000 000 SEK
Types
Pre-money valuation
265 000 000 SEK
Subscription block size
Minimum subscription
500
Record date
Offer status
Closed
Listing status
Listed
First trading date
19 Dec 2016
Issue terms
Institutions and those who left relations have priority.
Type
Price
Pre-money valuation
Time
New issue
1.50 SEK
34.5M SEK
09 Oct - 25 Oct 2019
Share issue in Acarix AB
Market
Nasdaq First North Sweden
Subscription period
09 Oct - 25 Oct 2019
Subscription price
1.50 SEK
Price per share
1.50 SEK
Target to raise
51 800 000 SEK
Types
Share issue
Pre-money valuation
34 500 000 SEK
Subscription block size
Minimum subscription
Record date
04 Oct 2019
Offer status
Active
Listing status
Listed
Issue terms
Preference right 3:2. One (1) existing share held on the record day entitles to three (3) subscription rights. Two (2) subscription rights entitle to subscribe for one (1) new share.
Comments for offer & related information
Acarix has received subscription commitments and underwriting guarantees from external investors totaling approximately SEK 43 million (approximately 83 per cent of the Rights Issue), of which approximately SEK 10 million relates to subscription commitments through transferred subscription rights and approximately SEK 33 million relate to issue guarantees.
People
Number of Employees
11 people
Christian Lindholm
CEO
Dr. Werner Braun
Chairman of the board
Denis Marie Gestin
Board member
Claus Asbjørn Andersson
Board member
Johanne Louise Braendgaard
Board member
Yunfei Hong
Board member
Ulf Rosén
Board member
Dr. Werner Braun
Board member
Company Details
Sector
HEALTH CARE

Address
World Trade Center
Zip code
211 11
City/district
Malmö
Country
Sweden (SE)
Registration number
559009-0667
LEI code
549300KP2XS4513DEI67
First trade date
19 Dec 2016
Registration date
26 Mar 2015
Short name
Acarix

We use cookies to make your experience using IPOhub better. By using our site you agree to our use of cookies. Learn More